title: Role of enteral nutrition supplemented with ebselen and EHEC in pancreatitis-associated multiple organ dysfunction in rats.
abstract: OBJECTIVE
  To investigate potential effects of ebselen and ethylhydroxyethyl cellulose (EHEC) on the acute phase responses and the severity of multiple organ dysfunction associated with acute pancreatitis.
  
  
  METHODS
  Acute pancreatitis was induced by intraductal infusion of 5% sodium taurodeoxycholate. The increase of total protein content in the BALF was used as an indication for acute lung injury, plasma amylase for pancreatic damage, plasma bilirubin for acute liver dysfunction, and plasma creatinine for acute kidney dysfunction. Levels of interleukin (IL)-6, macrophage inflammatory protein (MIP)-2 in the BALF were determined by ELISA.
  
  
  RESULTS
  There was a dose-related tendency for ebselen or EHEC alone to prevent organ dysfunction and reduce elevated plasma levels of IL-6 and ICAM-1 expression on circulating leukocytes 12 h after AP induction. The combination of ebselen and EHEC significantly prevented pancreatitis-induced multiple organ injury, IL-6 production and ICAM-1 expression in rats and exhibited better effects than either monocompound alone.
  
  
  CONCLUSIONS
  The combination of ebselen and EHEC may be a new potential for treatment of acute severe pancreatitis.
authors.affiliation: Department of Pulmonary Medicine, Zhongshan Hospital, Shanghai, China.
authors.forename: H
authors.initials: H
authors.lastname: Zhao
authors.forename: H-G
authors.initials: HG
authors.lastname: Lu
authors.forename: Y-B
authors.initials: YB
authors.lastname: Shi
authors.forename: L-M
authors.initials: LM
authors.lastname: Zhao
authors.forename: C
authors.initials: C
authors.lastname: Bai
authors.forename: X
authors.initials: X
authors.lastname: Wang
mesh_terms: D000681:Amylases / Q000097:blood; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001393:Azoles / Q000494:pharmacology*; D001663:Bilirubin / Q000097:blood; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D002482:Cellulose / Q000031:analogs & derivatives* / Q000494:pharmacology; D054426:Chemokine CXCL2; D019743:Chemokines, CXC / Q000276:immunology; D003401:Creatine / Q000097:blood; D004750:Enteral Nutrition; D007155:Immunologic Factors / Q000494:pharmacology*; D018799:Intercellular Adhesion Molecule-1 / Q000276:immunology; D015850:Interleukin-6 / Q000097:blood; D054833:Isoindoles; D008297:Male; D009000:Monocytes / Q000276:immunology; D009102:Multiple Organ Failure / Q000097:blood / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D016566:Organoselenium Compounds / Q000494:pharmacology*; D010195:Pancreatitis / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology; D011506:Proteins / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D013657:Taurodeoxycholic Acid
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001393:Azoles; D054426:Chemokine CXCL2; D019743:Chemokines, CXC; C513296:Cxcl2 protein, rat; D007155:Immunologic Factors; D015850:Interleukin-6; D054833:Isoindoles; D016566:Organoselenium Compounds; D011506:Proteins; C462399:ethyl(hydroxyethyl)cellulose; D018799:Intercellular Adhesion Molecule-1; C042986:ebselen; D013657:Taurodeoxycholic Acid; D002482:Cellulose; D000681:Amylases; D003401:Creatine; D001663:Bilirubin